Incorporating Ototoxicity Management into Clinical Pathways

Includes a Live Web Event on 12/14/2022 at 4:00 PM (EST)


Speakers:
Angela Garinis, PhD 
Carmen Brewer, PhD 
Gayla Poling, PhD

CEUs: 0.1 AAA/Tier 1 CEUs

Duration: 60 minutes

Instructional Level: Intermediate

Program Focus: Knowledge 

Description:
  

Incorporating ototoxicity management into patient-centered care is feasible and critical for maintaining quality of life in patients at risk for hearing, balance and/or vestibular loss across the lifespan. Monitoring for ototoxicity provides the opportunity to obtain a pathophysiological description of the longitudinal effects of the ototoxic agent on an individual’s auditory and vestibular systems. This information also aids our ability to address each patient’s needs and the identification of clinical risk factors associated with the development of ototoxicity in unique populations.  Thus, early identification, prevention, and mitigation of ototoxicity-related symptoms are recommended through the routine implementation of ototoxicity-monitoring protocols. 

Learning Outcomes: 

1. Identify current national guidelines and published consensus statements for ototoxicity monitoring protocols.
2. Discuss current gaps and barriers for implementing a successful ototoxicity management program across diverse clinical populations.
3. Describe screening measures and mobile technologies for potential use in an ototoxicity management program.  



image

Angela Garinis, PhD

Dr. Garinis, is a clinical researcher and assistant professor in the Oregon Hearing Research Center at Oregon Health & Science University in Portland, Oregon. She has grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation to investigate mechanisms associated with aminoglycoside-induced ototoxicity, as well as patient and clinical risk factors that contribute to a risk for developing ototoxic hearing loss.

image

Carmen Brewer, PhD 

Dr. Brewer is a clinical researcher and chief of the audiology unit at the National Institute on Deafness and Other Communication Disorders in Bethesda, Maryland. Her clinical and research interests include the genetics of hearing loss, identification of risk factors for ototoxicity, and the management of patients treated with ototoxic drugs.

image

Gayla Poling, PhD

Dr. Poling is the director of diagnostic audiology research at the Mayo Clinic in Rochester, Minnesota. Her clinical and research interests include ototoxicity management, complex care, and auditory diagnostics with a focus on early detection and prevention of hearing loss across the lifespan.

Key:

Complete
Failed
Available
Locked
Incorporating Ototoxicity Management into Clinical Pathways
12/14/2022 at 4:00 PM (EST)   |  60 minutes
12/14/2022 at 4:00 PM (EST)   |  60 minutes Incorporating Ototoxicity Management into Clinical Pathways